Session Type: ACR Poster Session C
Session Time: 9:00AM-11:00AM
Methods:In total 70 consecutive PsA patients [49 females (69%); with a median age (interquartile range, IQR) of 43 (17) years] according to the CASPAR criteria and 36 healthy control subjects [(23 females [63%]; with a median age (IQR) 38 (16) years] were included in the study. Serum periostin, Dkk-1 and sclerostin levels were measured by commercially available ELISA kits. We also assessed serum levels of high-sensitivity C-reactive protein (hs-CRP). Disease related characteristics of patients were evaluated by using BASDAI, BASFI, HAQ, DAS28. Because the data were not distributed homogenously the results are presented as median and interquartile range (IQR) and non-parametric tests were used for group comparisons.
Results: In our PsA group , median (IQR) duration of psoriasis and psoriatic arthritis were 13(20) and 6 (8) years, respectively. In total 27 patients were using corticosteroids, 41 metothrexate, 12 leflunomide and 23 tumor necrosis factor inhibitors. Some of the clinical and laboratory characteristics of patients and control subjects were shown in table. As expected serum CRP levels were significantly higher in PsA patients in comparison with control subjects. Serum periostin levels were not statistically different between study groups. However we found that circulating Dkk-1 and sclerostin levels were significantly lower in PsA patients. Serum Dkk-1 levels were associated with serum sclerostin levels (r=0.872 and P<0.001) and age (r=0.312 and P=0.008). Serum periostin, Dkk-1 and sclerostin levels were not different between PsA patients with and without axial incolvement.
Conclusion: Our results suggested that circulating Dkk-1 and sclerostin may have a role in disease susceptibility. Decreased Dkk-1 and sclerostin levels may contribute to the new bone formation, seen in the disease course, in patients with PsA. Table1. Some clinical and laboratory characteristics of study groups.
To cite this abstract in AMA style:Tarhan EF, DEMİREL B, Kozaci LD, Ozmen M, Türkmen İ, Bas Tomas NH, Akar S. Sclerostin and Dickkopf-1 but Not Periostin May Have a Role in Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/sclerostin-and-dickkopf-1-but-not-periostin-may-have-a-role-in-psoriatic-arthritis/. Accessed December 2, 2020.
« Back to 2016 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/sclerostin-and-dickkopf-1-but-not-periostin-may-have-a-role-in-psoriatic-arthritis/